IDEXX Laboratories Reports Director Departure and Officer Changes
Ticker: IDXX · Form: 8-K · Filed: Oct 7, 2025 · CIK: 874716
| Field | Detail |
|---|---|
| Company | Idexx Laboratories Inc /De (IDXX) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-compensation, director-changes
Related Tickers: IDXX
TL;DR
IDEXX director out, new board members in, exec pay details filed.
AI Summary
On October 6, 2025, IDEXX Laboratories, Inc. reported a departure of a director, effective October 6, 2025. The filing also announced the election of new directors and changes in officer compensation arrangements. Specific details regarding the compensation arrangements for certain officers were filed as exhibits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance matters such as director departures and elections, with no immediate financial implications disclosed.
Key Players & Entities
- IDEXX LABORATORIES, INC. (company) — Registrant
- October 6, 2025 (date) — Effective date of director departure and earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 000-19271 (company_id) — Commission File Number
- 01-0393723 (company_id) — IRS Employer Identification No.
- Westbrook, Maine (location) — Company business and mail address
FAQ
Who is the departing director from IDEXX Laboratories, Inc.?
The filing does not explicitly name the departing director, only stating that there was a departure of a director.
When was the director departure effective?
The departure of the director was effective on October 6, 2025.
What other governance changes were reported?
The filing also reported the election of directors and changes to compensatory arrangements for certain officers.
Where is IDEXX Laboratories, Inc. headquartered?
IDEXX Laboratories, Inc. is located at One IDEXX Drive, Westbrook, Maine.
What is the filing date for this Form 8-K?
This Form 8-K was filed on October 7, 2025, reporting events as of October 6, 2025.
Filing Stats: 813 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2025-10-07 07:06:51
Key Financial Figures
- $0.10 — ange on whichregistered Common Stock, $0.10 par value per share IDXX NASDAQ Glo
Filing Documents
- tm2528124d1_8k.htm (8-K) — 36KB
- tm2528124d1_ex99-1.htm (EX-99.1) — 7KB
- tm2528124d1_8kimg001.jpg (GRAPHIC) — 7KB
- tm2528124d1_ex99-1img001.jpg (GRAPHIC) — 2KB
- 0001104659-25-097319.txt ( ) — 231KB
- idxx-20251006.xsd (EX-101.SCH) — 3KB
- idxx-20251006_lab.xml (EX-101.LAB) — 33KB
- idxx-20251006_pre.xml (EX-101.PRE) — 22KB
- tm2528124d1_8k_htm.xml (XML) — 3KB
02. Departure of Directors or
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Election of New Director. Effective October 6, 2025, the board of directors (the "Board") of IDEXX Laboratories, Inc. (the "Company") elected Karen Peacock as an independent Class I Director and appointed her as a member of its Compensation and Talent Committee and Finance Committee. To effect Ms. Peacock's election as a Class I Director, the Board increased the number of Directors constituting the Board from ten to eleven and the number of Class I Directors from three to four. It is expected that Ms. Peacock will stand for election by stockholders as a Class I Director at the Company's 2027 annual meeting of stockholders. There are no related person transactions (or proposed related person transactions) with respect to Ms. Peacock reportable under Item 5.02(d) of Form 8-K and Item 404(a) of Regulation S-K since the beginning of the Company's last fiscal year. Ms. Peacock will receive the same compensation as is paid to the Company's other non-employee Directors, as described in the section entitled "Corporate Governance – Non-Employee Director Compensation" in the Company's Proxy Statement filed with the Securities and Exchange Commission on March 28, 2025, which description is incorporated herein by reference. The cash fee to be paid to Ms. Peacock in the fourth quarter of 2025 will be prorated to reflect the effective date of her election to the Board. Annual deferred stock unit or restricted stock unit and stock option grants were made to non-employee Directors on May 7, 2025, the date of the Company's 2025 annual meeting of stockholders. Since Ms. Peacock was not serving as a Director at that time, such grants will be made to her on December 1, 2025, and the award values will be prorated to reflect the portion of the year during which she will serve on the Board, specifically from October 6, 2025 until
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 5.02 shall be deemed to be furnished, and not filed. 99.1 Press Release entitled "IDEXX Laboratories Elects Karen Peacock to Board of Directors" dated October 7, 2025. 104 Cover Page Interactive Data File (embedded within Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES, INC. Date: October 7, 2025 By: /s/ Sharon E. Underberg Sharon E. Underberg Executive Vice President, General Counsel and Corporate Secretary 3